Elanco Animal Health Incorporated $ELAN Shares Sold by Algert Global LLC

Key Points

• Algert Global reduced its Elanco Animal Health stake by 19% in the second quarter, selling 42,410 shares and retaining 180,430 shares valued at approximately $4.44 million. Institutional investors and hedge funds collectively own 97.48% of ELAN.
• Analyst sentiment remains positive, with Elanco receiving a consensus “Moderate Buy” rating and an average price target of $29.09. Recent targets range from $26 to $33.
• Elanco’s latest quarterly results exceeded expectations: adjusted earnings were $0.34 per share versus the $0.27 consensus, while revenue rose 10.2% year over year to $1.37 billion. Insiders have also purchased 63,198 shares worth about $1.47 million over the past 90 days.

Algert Global LLC trimmed its holdings in Elanco Animal Health Incorporated (NYSE:ELAN - Free Report) by 19.0% during the 2nd quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 180,430 shares of the company's stock after selling 42,410 shares during the quarter. Algert Global LLC's holdings in Elanco Animal Health were worth $4,440,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in ELAN. NewEdge Advisors LLC boosted its stake in shares of Elanco Animal Health by 133.7% in the fourth quarter. NewEdge Advisors LLC now owns 1,096 shares of the company's stock worth $25,000 after buying an additional 627 shares during the last quarter. Mitsubishi UFJ Asset Management Co. Ltd. purchased a new position in Elanco Animal Health during the second quarter valued at approximately $38,000. Root Financial Partners LLC raised its position in Elanco Animal Health by 50.7% during the fourth quarter. Root Financial Partners LLC now owns 1,759 shares of the company's stock valued at $40,000 after acquiring an additional 592 shares in the last quarter. Uniplan Investment Counsel Inc. acquired a new position in Elanco Animal Health in the fourth quarter valued at approximately $41,000. Finally, Torren Management LLC acquired a new position in Elanco Animal Health in the fourth quarter valued at approximately $46,000. 97.48% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

ELAN has been the topic of a number of analyst reports. TD Cowen raised their price objective on shares of Elanco Animal Health from $31.00 to $32.00 and gave the stock a "buy" rating in a research note on Thursday, June 18th. Wall Street Zen cut shares of Elanco Animal Health from a "strong-buy" rating to a "buy" rating in a research note on Sunday, May 24th. Piper Sandler reissued an "overweight" rating on shares of Elanco Animal Health in a report on Monday, June 29th. UBS Group raised their price target on shares of Elanco Animal Health from $31.00 to $33.00 and gave the company a "buy" rating in a research report on Thursday, August 6th. Finally, Morgan Stanley lifted their price objective on shares of Elanco Animal Health from $23.00 to $26.00 and gave the company an "equal weight" rating in a report on Wednesday, July 22nd. One investment analyst has rated the stock with a Strong Buy rating, nine have issued a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, Elanco Animal Health presently has an average rating of "Moderate Buy" and a consensus target price of $29.09.

Insider Buying and Selling

In related news, Director Michael J. Harrington acquired 5,000 shares of Elanco Animal Health stock in a transaction on Wednesday, August 12th. The stock was bought at an average cost of $21.82 per share, for a total transaction of $109,100.00. Following the completion of the transaction, the director owned 131,451 shares of the company's stock, valued at approximately $2,868,260.82. The trade was a 3.95% increase in their position. The acquisition was disclosed in a legal filing with the SEC, which is available through this link. Also, insider Shiv O'neill acquired 3,998 shares of the firm's stock in a transaction on Tuesday, August 18th. The shares were bought at an average cost of $23.58 per share, for a total transaction of $94,272.84. Following the completion of the acquisition, the insider owned 87,832 shares of the company's stock, valued at approximately $2,071,078.56. This represents a 4.77% increase in their ownership of the stock. The SEC filing for this purchase provides additional information. Insiders have bought 63,198 shares of company stock worth $1,473,109 in the last 90 days. 1.14% of the stock is owned by insiders.

Elanco Animal Health Stock Down 2.2%

Shares of ELAN opened at $24.52 on Friday. The firm has a market cap of $12.25 billion, a P/E ratio of -59.80, a PEG ratio of 1.50 and a beta of 1.67. Elanco Animal Health Incorporated has a 12 month low of $17.11 and a 12 month high of $27.98. The stock's 50 day moving average is $24.62 and its two-hundred day moving average is $24.01. The company has a current ratio of 2.05, a quick ratio of 1.10 and a debt-to-equity ratio of 0.58.

Elanco Animal Health (NYSE:ELAN - Get Free Report) last announced its earnings results on Wednesday, August 5th. The company reported $0.34 earnings per share for the quarter, topping the consensus estimate of $0.27 by $0.07. Elanco Animal Health had a positive return on equity of 8.13% and a negative net margin of 3.96%.The business had revenue of $1.37 billion during the quarter, compared to the consensus estimate of $1.31 billion. During the same period in the prior year, the company posted $0.26 EPS. The business's quarterly revenue was up 10.2% on a year-over-year basis. Elanco Animal Health has set its Q3 2026 guidance at 0.190-0.220 EPS and its FY 2026 guidance at 1.100-1.160 EPS. Analysts predict that Elanco Animal Health Incorporated will post 1.12 earnings per share for the current fiscal year.

Elanco Animal Health Company Profile

Elanco Animal Health Inc is a global leader in animal health dedicated to improving food and companion animal well-being. The company develops, manufactures and markets a range of products, including parasiticides, vaccines, antibiotics and feed additives designed to prevent and treat disease in livestock and pets. Elanco's portfolio spans both food-producing animals—such as cattle, swine, poultry and aquaculture—and companion animals, with offerings that support parasite control, pain management and infectious disease prevention.

Originally founded as the animal health division of Eli Lilly and Company in the mid-20th century, Elanco was spun off into an independent publicly traded company in 2018.

Want to see what other hedge funds are holding ELAN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Elanco Animal Health Incorporated (NYSE:ELAN - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source